MAIA Biotechnology (MAIA) Change in Cash (2021 - 2026)
MAIA Biotechnology (MAIA) posted quarterly Change in Cash of $25.8 million for Q1 2026, up 1940.82% year-over-year from $1.3 million in Q1 2025, and up 1253.02% quarter-over-quarter from -$2.2 million in Q4 2025.
MAIA Biotechnology (MAIA) Change in Cash (2021 - 2026) Analysis & Trends
MAIA Biotechnology (MAIA) has reported Change in Cash for 6 consecutive years, with $25.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Cash rose 1940.82% year-over-year to $25.8 million; the TTM figure through Mar 2026 stood at $23.5 million (up 808.61% YoY), while the FY2025 annual figure was -$943267.0, down 138.49% from the prior year.
- Change in Cash improved to $25.8 million in Q1 2026 per MAIA's latest filing, from -$2.2 million in the prior quarter.
- Across five years, Change in Cash topped out at $25.8 million in Q1 2026 and bottomed at -$3.4 million in Q1 2023.
- Historically, Change in Cash has averaged $1.4 million across 5 years, with a median of $747214.0 in 2025.
- Annual changes were most pronounced in 2023 — Change in Cash tumbled 1098.09% — and 2026, when it soared 1940.82%.
- MAIA Biotechnology's Change in Cash stood at -$3.1 million in 2022, then jumped by 133.61% to $1.0 million in 2023, then dropped by 12.96% to $910514.0 in 2024, then sank by 345.32% to -$2.2 million in 2025, then surged by 1253.02% to $25.8 million in 2026.
- Business Quant data shows MAIA's Change in Cash at $25.8 million in Q1 2026, -$2.2 million in Q4 2025, and $747214.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | MAIA Biotechnology | 84.50 Mn | 56.91 Mn | - | -6.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.82 Mn |
| Mar 31, 2026 | 25.76 Mn |
| Dec 31, 2025 | -2.23 Mn |
| Sep 30, 2025 | 747,214.00 |
| Jun 30, 2025 | -718,774.00 |
| Mar 31, 2025 | 1.26 Mn |
| Dec 31, 2024 | 910,514.00 |
| Sep 30, 2024 | -2.89 Mn |
| Jun 30, 2024 | 3.31 Mn |
| Mar 31, 2024 | 1.12 Mn |
| Dec 31, 2023 | 1.05 Mn |
| Sep 30, 2023 | -3.04 Mn |
| Jun 30, 2023 | 1.56 Mn |
| Mar 31, 2023 | -3.36 Mn |
| Dec 31, 2022 | -3.11 Mn |
| Sep 30, 2022 | 5.91 Mn |
| Jun 30, 2022 | -2.14 Mn |
| Mar 31, 2022 | -280,832.00 |
| Dec 31, 2021 | -378,212.00 |
| Sep 30, 2021 | 4.17 Mn |